BACKGROUND Recent studies indicate a possible relationship between thyroid diseases and breast cancer in vivo. In addition, oestrogen-like effects of thyroid hormones on breast cancer cell growth are seen in vitro. Therefore, this prospective observational study evaluated thyroid function in breast cancer patients, women with the fibrocystic disease and healthy controls. MATERIALS AND METHODSThis was a prospective observational study. Pre-treatment group consisted of breast cancer patients who at the initial time of diagnosis (n= 28), post-treatment group comprising of patients who had undergone either chemotherapy/ radiotherapy or hormone therapy for their disease (n= 37). The fibrocystic group comprising of patients with benign breast tumour (n= 21) and 51 healthy control group consisted of members of the public with no prior history of breast cancer or other cancer-related disorders (n= 51) were included in the study. Thyroid history was reported. Thyroid hormones (FT4, FT3, TSH, T3, T4) and thyroid antibodies (TPO. Ab and TG. Ab) were determined. The Kruskal-Wallis H and Mann-Whitney U tests (p < 0.005 significant) were used for statistical analysis. RESULTSFree thyroxine measurements showed significant difference comparing both CA breast patients, pre-treatment (p= 0.009) and post-treatment (p= 0.001), respectively to the control group. There was no significant difference in free thyroxine levels between fibrocystic patients and control groups (p= 0.917) as well as a non-significant difference in free thyroxine levels was found between fibrocystic patients and post-treatment CA breast patients (p= 0.079). There was no significant difference in thyroxine (T4) measurement between breast cancer groups, fibrocystic group and normal healthy control group (p > 0.05). The free triiodothyronine (T3) measurements showed no significant difference between breast cancer groups, fibrocystic group and normal healthy control group (p > 0.05). The thyrotropin (TSH) measurements showed significant difference comparing both CA breast patients, pre-treatment (p= 0.016) and post-treatment (p= 0.01) respectively to the control group. The thyroid peroxidase antibodies (anti-TPO) measurements showed no significant difference between breast cancer groups, fibrocystic group and normal healthy control group (p > 0.05). CONCLUSIONThe subclinical hypothyroidism was seen more frequently in breast cancer patients, changing levels of thyroid hormones suggested dysregulation in breast cancer patients. These data must be confirmed in large patient's prospective observational study. Financial or Other Competing Interest': None. Submission 13-01-2018, Peer Review 25-01-2018, Acceptance 27-01-2018, Published 05-02-2018. Corresponding Author: Dr. Jagannadha Rao Peela, Department of Biochemistry and Medical Genetics, School of Medicine, St. Matthew's University, Leeward 3, Regatta Office Park, Grand Cayman, Cayman Islands-KY1-1204. E-mail: pjrao@stmatthews.edu DOI: 10.14260/jemds/2018 The World Health Organization (WHO) clas...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.